{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:46:30Z","timestamp":1790999190270,"version":"4.1.0"},"reference-count":107,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:00:00Z","timestamp":1633392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>In the past few years, an increasing amount of studies primarily based on experimental models have investigated the existence of distinct \u03b1-synuclein strains and their different pathological effects. This novel concept could shed light on the heterogeneous nature of \u03b1-synucleinopathies, a group of disorders that includes Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, which share as their key-molecular hallmark the abnormal aggregation of \u03b1-synuclein, a process that seems pivotal in disease pathogenesis according to experimental observations. However, the etiology of \u03b1-synucleinopathies and the initial events leading to the formation of \u03b1-synuclein aggregates remains elusive. Hence, the hypothesis that structurally distinct fibrillary assemblies of \u03b1-synuclein could have a causative role in the different disease phenotypes and explain, at least to some extent, their specific neurodegenerative, disease progression, and clinical presentation patterns is very appealing. Moreover, the presence of different \u03b1-synuclein strains might represent a potential biomarker for the diagnosis of these neurodegenerative disorders. In this regard, the recent use of super resolution techniques and protein aggregation assays has offered the possibility, on the one hand, to elucidate the conformation of \u03b1-synuclein pathogenic strains and, on the other hand, to cyclically amplify to detectable levels low amounts of \u03b1-synuclein strains in blood, cerebrospinal fluid and peripheral tissue from patients. Thus, the inclusion of these techniques could facilitate the differentiation between \u03b1-synucleinopathies, even at early stages, which is crucial for successful therapeutic intervention. This mini-review summarizes the current knowledge on \u03b1-synuclein strains and discusses its possible applications and potential benefits.<\/jats:p>","DOI":"10.3389\/fneur.2021.737195","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:57:05Z","timestamp":1633395425000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["The Concept of \u03b1-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders"],"prefix":"10.3389","volume":"12","author":[{"given":"Katja","family":"Malfertheiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Stefanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Heras-Garvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of alpha-synuclein: from structure and toxicity to therapeutic target","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat Rev Neurosci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"584536","DOI":"10.3389\/fnsyn.2020.584536","article-title":"From synaptic protein to prion: the long and controversial journey of \u03b1-synuclein","volume":"12","author":"Heras-Garvin","year":"2020","journal-title":"Front Synaptic Neurosci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0304-3940(98)00504-7","article-title":"Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies","volume":"251","author":"Spillantini","year":"1998","journal-title":"Neurosci Lett."},{"key":"B4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.lpm.2017.01.001","article-title":"Epidemiology, environmental risk factors and genetics of Parkinson's disease","volume":"46","author":"Delamarre","year":"2017","journal-title":"Presse Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00702-017-1821-9","article-title":"Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies","volume":"125","author":"Jellinger","year":"2018","journal-title":"J Neural Transm (Vienna)."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1002\/mds.23394","article-title":"What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?","volume":"25","author":"Gallagher","year":"2010","journal-title":"Mov Disord."},{"key":"B7","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.nbd.2009.05.023","article-title":"Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions","volume":"35","author":"Chu","year":"2009","journal-title":"Neurobiol Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1172\/JCI32806","article-title":"Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy","volume":"118","author":"Martinez-Vicente","year":"2008","journal-title":"J Clin Invest."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1038\/emboj.2012.170","article-title":"Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences","volume":"31","author":"Exner","year":"2012","journal-title":"EMBO J."},{"key":"B10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.neuint.2012.11.015","article-title":"Genetics and iron in the systems biology of Parkinson's disease and some related disorders","volume":"62","author":"Funke","year":"2013","journal-title":"Neurochem Int."},{"key":"B11","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1016\/S1353-8020(11)70065-7","article-title":"Neuroinflammation in Parkinson's disease","volume":"18","author":"Hirsch","year":"2012","journal-title":"Parkinsonism Relat Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/WNL.65.12.1992-a","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium","volume":"65","author":"McKeith","year":"2005","journal-title":"Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","article-title":"Dementia with Lewy bodies: an update and outlook","volume":"14","author":"Outeiro","year":"2019","journal-title":"Mol Neurodegener."},{"key":"B14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/jnc.14698","article-title":"Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies - current issues and future directions","volume":"150","author":"Walker","year":"2019","journal-title":"J Neurochem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40035-020-0185-5","article-title":"Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions","volume":"9","author":"Kaji","year":"2020","journal-title":"Transl Neurodegener."},{"key":"B16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneurol.2017.26","article-title":"Multiple system atrophy: insights into a rare and debilitating movement disorder","volume":"13","author":"Krismer","year":"2017","journal-title":"Nat Rev Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/bpa.12678","article-title":"Oligodendroglial alpha-synucleinopathy-driven neuroinflammation in multiple system atrophy","volume":"29","author":"Hoffmann","year":"2019","journal-title":"Brain Pathol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3389\/fncel.2015.00437","article-title":"Neuroinflammation in multiple system atrophy: response to and cause of alpha-synuclein aggregation","volume":"9","author":"Vieira","year":"2015","journal-title":"Front Cell Neurosci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/mds.27620","article-title":"Widespread microglial activation in multiple system atrophy","volume":"34","author":"Kubler","year":"2019","journal-title":"Mov Disord."},{"key":"B20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/jnnp.60.1.98","article-title":"Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy","volume":"60","author":"Schwarz","year":"1996","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B21","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00401-020-02126-w","article-title":"T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease","volume":"139","author":"Williams","year":"2020","journal-title":"Acta Neuropathol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1056\/NEJMra1311488","article-title":"Multiple-system atrophy","volume":"372","author":"Fanciulli","year":"2015","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00415-005-0617-2","article-title":"Progression of parkinsonism in multiple system atrophy","volume":"252","author":"Seppi","year":"2005","journal-title":"J Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3233\/JAD-170397","article-title":"Multiple system atrophy: an oligodendroglioneural synucleinopathy1","volume":"62","author":"Jellinger","year":"2018","journal-title":"J Alzheimers Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.mayocp.2019.03.009","article-title":"Pure autonomic failure","volume":"94","author":"Coon","year":"2019","journal-title":"Mayo Clin Proc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nrneurol.2017.157","article-title":"Idiopathic REM sleep behaviour disorder and neurodegeneration - an update","volume":"14","author":"Hogl","year":"2018","journal-title":"Nat Rev Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1212\/WNL.0000000000003737","article-title":"Pure autonomic failure: predictors of conversion to clinical CNS involvement","volume":"88","author":"Singer","year":"2017","journal-title":"Neurology."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1212\/01.WNL.0000138500.73671.DC","article-title":"Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies","volume":"63","author":"Kaufmann","year":"2004","journal-title":"Neurology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1093\/brain\/awv274","article-title":"Clinical features and autonomic testing predict survival in multiple system atrophy","volume":"138","author":"Coon","year":"2015","journal-title":"Brain."},{"key":"B30","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1212\/WNL.0b013e3181d26982","article-title":"Pure autonomic failure: a restricted Lewy body synucleinopathy or early Parkinson disease?","volume":"74","author":"Kaufmann","year":"2010","journal-title":"Neurology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00415-009-5240-1","article-title":"Non-motor symptoms in Parkinson's disease","volume":"256","author":"Park","year":"2009","journal-title":"J Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"9421098","DOI":"10.1155\/2018\/9421098","article-title":"REM Sleep Behavior Disorder (RBD) in Dementia with Lewy Bodies (DLB)","volume":"2018","author":"Chan","year":"2018","journal-title":"Behav Neurol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.clinph.2018.05.003","article-title":"Rapid eye movement sleep behavior disorder and the link to alpha-synucleinopathies","volume":"129","author":"Barone","year":"2018","journal-title":"Clin Neurophysiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(13)70056-5","article-title":"Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study","volume":"12","author":"Iranzo","year":"2013","journal-title":"Lancet Neurol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.sleep.2012.10.009","article-title":"Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series","volume":"14","author":"Schenck","year":"2013","journal-title":"Sleep Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nature16531","article-title":"Structural disorder of monomeric alpha-synuclein persists in mammalian cells","volume":"530","author":"Theillet","year":"2016","journal-title":"Nature."},{"key":"B37","doi-asserted-by":"publisher","first-page":"15345","DOI":"10.1074\/jbc.M111.318949","article-title":"alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and Escherichia coli exists predominantly as disordered monomer","volume":"287","author":"Fauvet","year":"2012","journal-title":"J Biol Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","article-title":"alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation","volume":"477","author":"Bartels","year":"2011","journal-title":"Nature."},{"key":"B39","doi-asserted-by":"publisher","first-page":"17797","DOI":"10.1073\/pnas.1113260108","article-title":"A soluble alpha-synuclein construct forms a dynamic tetramer","volume":"108","author":"Wang","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B40","doi-asserted-by":"publisher","first-page":"4897","DOI":"10.1073\/pnas.97.9.4897","article-title":"Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation","volume":"97","author":"Serpell","year":"2000","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B41","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1042\/BJ20111924","article-title":"Toxic prefibrillar alpha-synuclein amyloid oligomers adopt a distinctive antiparallel beta-sheet structure","volume":"443","author":"Celej","year":"2012","journal-title":"Biochem J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"41051","DOI":"10.1038\/srep41051","article-title":"Evidence for intramolecular antiparallel beta-sheet structure in alpha-synuclein fibrils from a combination of two-dimensional infrared spectroscopy and atomic force microscopy","volume":"7","author":"Roeters","year":"2017","journal-title":"Sci Rep."},{"key":"B43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nsmb.3194","article-title":"Solid-state NMR structure of a pathogenic fibril of full-length human alpha-synuclein","volume":"23","author":"Tuttle","year":"2016","journal-title":"Nat Struct Mol Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1073\/pnas.0407146102","article-title":"Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein","volume":"102","author":"Bertoncini","year":"2005","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13024-020-00368-6","article-title":"Initiation and propagation of alpha-synuclein aggregation in the nervous system","volume":"15","author":"Hijaz","year":"2020","journal-title":"Mol Neurodegener."},{"key":"B46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13024-019-0329-1","article-title":"Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles","volume":"14","author":"Meade","year":"2019","journal-title":"Mol Neurodegener."},{"key":"B47","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.stemcr.2015.07.002","article-title":"Alpha-synuclein expression in the oligodendrocyte lineage: an in vitro and in vivo study using rodent and human models","volume":"5","author":"Djelloul","year":"2015","journal-title":"Stem Cell Reports."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s00702-005-0378-1","article-title":"Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia","volume":"112","author":"Miller","year":"2005","journal-title":"J Neural Transm (Vienna)."},{"key":"B49","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/glia.22653","article-title":"Alpha-synuclein mRNA expression in oligodendrocytes in MSA","volume":"62","author":"Asi","year":"2014","journal-title":"Glia."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e39465","DOI":"10.1371\/journal.pone.0039465","article-title":"Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo","volume":"7","author":"Angot","year":"2012","journal-title":"PLoS ONE."},{"key":"B51","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/glia.22611","article-title":"Alpha-synuclein transfers from neurons to oligodendrocytes","volume":"62","author":"Reyes","year":"2014","journal-title":"Glia."},{"key":"B52","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/jnc.14806","article-title":"Cellular models of alpha-synuclein toxicity and aggregation","volume":"150","author":"Delenclos","year":"2019","journal-title":"J Neurochem."},{"key":"B55","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/JPD-2011-11043","article-title":"Mouse models of cognitive deficits due to alpha-synuclein pathology","volume":"1","author":"Magen","year":"2011","journal-title":"J Parkinsons Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0346-8","article-title":"Models of multiple system atrophy","volume":"51","author":"Lee","year":"2019","journal-title":"Exp Mol Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrn.2017.75","article-title":"Animal models of alpha-synucleinopathy for Parkinson disease drug development","volume":"18","author":"Koprich","year":"2017","journal-title":"Nat Rev Neurosci."},{"key":"B58","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3389\/fnins.2018.00621","article-title":"Quality over quantity: advantages of using alpha-synuclein preformed fibril triggered synucleinopathy to model idiopathic Parkinson's disease","volume":"12","author":"Duffy","year":"2018","journal-title":"Front Neurosci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/mds.26370","article-title":"Alpha-synuclein propagation: new insights from animal models","volume":"31","author":"Dehay","year":"2016","journal-title":"Mov Disord."},{"key":"B60","doi-asserted-by":"publisher","first-page":"139","DOI":"10.14802\/jmd.19046","article-title":"Modeling alpha-Synuclein Propagation with Preformed Fibril Injections","volume":"12","author":"Chung","year":"2019","journal-title":"J Mov Disord."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/brain\/awt037","article-title":"Prion-like spreading of pathological alpha-synuclein in brain","volume":"136","author":"Masuda-Suzukake","year":"2013","journal-title":"Brain."},{"key":"B62","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1126\/science.1227157","article-title":"Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice","volume":"338","author":"Luk","year":"2012","journal-title":"Science."},{"key":"B63","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00401-017-1792-9","article-title":"Spread of aggregates after olfactory bulb injection of alpha-synuclein fibrils is associated with early neuronal loss and is reduced long term","volume":"135","author":"Rey","year":"2018","journal-title":"Acta Neuropathol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"10732","DOI":"10.1073\/pnas.1321785111","article-title":"Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology and a rapid-onset motor phenotype in transgenic mice","volume":"111","author":"Sacino","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B65","doi-asserted-by":"publisher","first-page":"9182","DOI":"10.1128\/JVI.01399-16","article-title":"Neuroinvasion of alpha-synuclein prionoids after intraperitoneal and intraglossal inoculation","volume":"90","author":"Breid","year":"2016","journal-title":"J Virol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.neuron.2019.05.035","article-title":"Transneuronal propagation of pathologic alpha-synuclein from the gut to the brain models Parkinson's disease","volume":"103","author":"Kim","year":"2019","journal-title":"Neuron"},{"key":"B67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13024-018-0257-5","article-title":"Inoculation of alpha-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve","volume":"13","author":"Uemura","year":"2018","journal-title":"Mol Neurodegener."},{"key":"B68","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41467-019-14189-9","article-title":"Autonomic ganglionic injection of alpha-synuclein fibrils as a model of pure autonomic failure alpha-synucleinopathy","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/ncomms3575","article-title":"Structural and functional characterization of two alpha-synuclein strains","volume":"4","author":"Bousset","year":"2013","journal-title":"Nat Commun."},{"key":"B70","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature14547","article-title":"alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration","volume":"522","author":"Peelaerts","year":"2015","journal-title":"Nature."},{"key":"B71","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41593-019-0541-x","article-title":"alpha-Synuclein strains target distinct brain regions and cell types","volume":"23","author":"Lau","year":"2020","journal-title":"Nat Neurosci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"19555","DOI":"10.1073\/pnas.1318268110","article-title":"Transmission of multiple system atrophy prions to transgenic mice","volume":"110","author":"Watts","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B73","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/ana.24066","article-title":"Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys","volume":"75","author":"Recasens","year":"2014","journal-title":"Ann Neurol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"E5308","DOI":"10.1073\/pnas.1514475112","article-title":"Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism","volume":"112","author":"Prusiner","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B75","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40478-015-0254-7","article-title":"Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein","volume":"3","author":"Bernis","year":"2015","journal-title":"Acta Neuropathol Commun."},{"key":"B76","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40478-019-0733-3","article-title":"Comparative analyses of the in vivo induction and transmission of alpha-synuclein pathology in transgenic mice by MSA brain lysate and recombinant alpha-synuclein fibrils","volume":"7","author":"Dhillon","year":"2019","journal-title":"Acta Neuropathol Commun."},{"key":"B77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40478-018-0532-2","article-title":"Potent prion-like behaviors of pathogenic alpha-synuclein and evaluation of inactivation methods","volume":"6","author":"Tarutani","year":"2018","journal-title":"Acta Neuropathol Commun."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1074\/jbc.RA118.004471","article-title":"Parkinson's disease and multiple system atrophy have distinct alpha-synuclein seed characteristics","volume":"294","author":"Yamasaki","year":"2019","journal-title":"J Biol Chem."},{"key":"B79","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00401-020-02163-5","article-title":"Evidence of distinct alpha-synuclein strains underlying disease heterogeneity","volume":"142","author":"Holec","year":"2021","journal-title":"Acta Neuropathol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1038\/s41467-019-13564-w","article-title":"Structural heterogeneity of alpha-synuclein fibrils amplified from patient brain extracts","volume":"10","author":"Strohaker","year":"2019","journal-title":"Nat Commun."},{"key":"B81","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","article-title":"Discriminating alpha-synuclein strains in Parkinson's disease and multiple system atrophy","volume":"578","author":"Shahnawaz","year":"2020","journal-title":"Nature."},{"key":"B82","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41586-020-2317-6","article-title":"Structures of alpha-synuclein filaments from multiple system atrophy","volume":"585","author":"Schweighauser","year":"2020","journal-title":"Nature."},{"key":"B83","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","article-title":"The structural differences between patient-derived alpha-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies","volume":"139","author":"Van der Perren","year":"2020","journal-title":"Acta Neuropathol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-018-0104-4","article-title":"Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies","volume":"557","author":"Peng","year":"2018","journal-title":"Nature."},{"key":"B85","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00401-019-01959-4","article-title":"Multiple system atrophy prions retain strain specificity after serial propagation in two different Tg(SNCA*A53T) mouse lines","volume":"137","author":"Woerman","year":"2019","journal-title":"Acta Neuropathol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/ana.21465","article-title":"Multiple system atrophy: a primary oligodendrogliopathy","volume":"64","author":"Wenning","year":"2008","journal-title":"Ann Neurol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41582-019-0244-7","article-title":"Ageing as a risk factor for neurodegenerative disease","volume":"15","author":"Hou","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5607\/en.2014.23.4.277","article-title":"Multiple system atrophy: genetic or epigenetic?","volume":"23","author":"Sturm","year":"2014","journal-title":"Exp Neurobiol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00401-021-02316-0","article-title":"Multiple system atrophy-associated oligodendroglial protein p25alpha stimulates formation of novel alpha-synuclein strain with enhanced neurodegenerative potential","volume":"142","author":"Ferreira","year":"2021","journal-title":"Acta Neuropathol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/nan.12304","article-title":"Review: Multiple system atrophy: emerging targets for interventional therapies","volume":"42","author":"Stefanova","year":"2016","journal-title":"Neuropathol Appl Neurobiol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1212\/WNL.0000000000001807","article-title":"When DLB, PD, and PSP masquerade as MSA: an autopsy study of 134 patients","volume":"85","author":"Koga","year":"2015","journal-title":"Neurology."},{"key":"B92","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3389\/fneur.2018.00415","article-title":"Are we ready for detecting alpha-synuclein prone to aggregation in patients? The case of \u201cprotein-misfolding cyclic amplification\u201d and \u201creal-time quaking-induced conversion\u201d as diagnostic tools","volume":"9","author":"Paciotti","year":"2018","journal-title":"Front Neurol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jamaneurol.2016.4547","article-title":"Development of a biochemical diagnosis of Parkinson disease by detection of alpha-synuclein misfolded aggregates in cerebrospinal fluid","volume":"74","author":"Shahnawaz","year":"2017","journal-title":"JAMA Neurol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/jnc.14809","article-title":"Parkinson's disease biomarkers based on alpha-synuclein","volume":"150","author":"Fayyad","year":"2019","journal-title":"J Neurochem."},{"key":"B95","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00702-012-0784-0","article-title":"alpha-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system","volume":"119","author":"Mollenhauer","year":"2012","journal-title":"J Neural Transm (Vienna)."},{"key":"B96","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fnmol.2020.00038","article-title":"CNS-derived blood exosomes as a promising source of biomarkers: opportunities and challenges","volume":"13","author":"Hornung","year":"2020","journal-title":"Front Mol Neurosci."},{"key":"B97","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/brain\/awv346","article-title":"Induction of alpha-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies","volume":"139","author":"Stuendl","year":"2016","journal-title":"Brain."},{"key":"B98","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ana.25446","article-title":"Seeding variability of different alpha synuclein strains in synucleinopathies","volume":"85","author":"Candelise","year":"2019","journal-title":"Ann Neurol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-020-02160-8","article-title":"Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies","volume":"140","author":"Rossi","year":"2020","journal-title":"Acta Neuropathol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ana.25824","article-title":"Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from lewy body synucleinopathies","volume":"88","author":"Singer","year":"2020","journal-title":"Ann Neurol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/ana.26089","article-title":"Alpha-synuclein oligomers and neurofilament light chain predict phenoconversion of pure autonomic failure","volume":"89","author":"Singer","year":"2021","journal-title":"Ann Neurol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S1474-4422(20)30449-X","article-title":"Detection of alpha-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study","volume":"20","author":"Iranzo","year":"2021","journal-title":"Lancet Neurol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/brain\/awab005","article-title":"Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder","volume":"144","author":"Stefani","year":"2021","journal-title":"Brain."},{"key":"B104","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1096\/fj.03-1449com","article-title":"Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease","volume":"20","author":"El-Agnaf","year":"2006","journal-title":"FASEB J."},{"key":"B105","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00401-021-02324-0","article-title":"alpha-Synuclein in blood exosomes immunoprecipitated using neuronal and oligodendroglial markers distinguishes Parkinson's disease from multiple system atrophy","volume":"142","author":"Dutta","year":"2021","journal-title":"Acta Neuropathol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamaneurol.2020.3311","article-title":"Skin alpha-synuclein aggregation seeding activity as a novel biomarker for Parkinson disease","volume":"78","author":"Wang","year":"2020","journal-title":"JAMA Neurol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.3390\/ijms21082801","article-title":"Analysis of protein conformational strains-A key for new diagnostic methods of human diseases","volume":"21","author":"Surguchov","year":"2020","journal-title":"Int J Mol Sci."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.737195\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T00:57:08Z","timestamp":1633395428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.737195\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,5]]},"references-count":107,"alternative-id":["10.3389\/fneur.2021.737195"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.737195","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,5]]},"article-number":"737195"}}